{"entity":{"id":"nct05417789","kind":"trial","name":"Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)","aka":["TANGENT"],"tldr":"A phase 3 trial testing Emactuzumab in tenosynovial giant cell tumour, active and no longer recruiting.","summary":"Study of Emactuzumab for Tenosynovial Giant Cell Tumour (TGCT) is a phase 3 interventional study registered as NCT05417789, led by SynOx Therapeutics, and active but no longer recruiting on the registry. Official title: A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour. Planned enrolment is 128 participants (estimated). The study started in 2024-10-09 and primary completion is expected in 2025-12-23. No results have been posted on ClinicalTrials.gov.","status":"active","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT05417789","url":"https://clinicaltrials.gov/study/NCT05417789"}],"tags":["ctgov-ingest"],"related":[],"cancers":["tenosynovial-giant-cell-tumour"],"sections":[],"technologies":[],"targets":[],"drugs":["emactuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05417789","phase":"3","setting":"A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects With Tenosynovial Giant Cell Tumour","sponsor":"SynOx Therapeutics","started":"2024-10-09","startedType":"actual","enrolled":128,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05417789/","neighbours":{"cancer":[{"id":"tenosynovial-giant-cell-tumour","kind":"cancer","name":"Tenosynovial giant cell tumour (TGCT)","route":"/cancers/tenosynovial-giant-cell-tumour/"}],"drug":[{"id":"emactuzumab","kind":"drug","name":"Emactuzumab","route":"/drugs/emactuzumab/"}]}}